Opinion on R&D in Europe

Published within

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Microsoft: strong iTV deals let down by software

The decision comes a day after European cable group UPC announced it would not include Microsoft software in its set-top boxes. In Europe, Microsoft's strategy of buying stakes in cable groups to promote its iTV software has been scuppered by the software's quality. Unless Microsoft gets the software working well enough soon, it risks the same happening in the US.

Published By Datamonitor
04 Dec 2001
CommentWire
CommentWire

Metabolic syndrome: a future candidate for treatment

A long-term Finnish study has found that metabolic syndrome, which is similar to pre-diabetic conditions, is associated with an increased risk of mortality cardiovascular disease. Pharmacological therapy targeting metabolic syndrome may reduce this associated risk, but this has yet to be demonstrated in clinical trials.

Published By Datamonitor
05 Dec 2002
Expert View
Expert View

Merck: the victim of definitions

Merck has been forced to concede ground to its rival Pharmacia over the development of COX-II inhibitors, predominantly used for the relief of signs and symptoms of arthritis. The big pharma has withdrawn its application for Arcoxia's FDA approval - but how severe will the cost of the drug's false start prove?

Published By Datamonitor
05 Apr 2002
CommentWire
CommentWire

Merck: full of hope for Erbitux

Merck has announced an independent positive assessment of its Erbitux trial and hopes for approval in Europe. The potential market for the colorectal cancer treatment is huge, but Erbitux has a colorful history and Merck may have difficulty distancing the drug from its unfortunate past.

Published By Datamonitor
31 Mar 2003
CommentWire
CommentWire

Merck: EFFECT trial puts Fosamax ahead of Evista

A head to head trial between osteoporosis drugs Fosamax (Merck) and Evista (Lilly) indicates that Fosamax causes greater bone mineral density increases over 12 months than Evista in postmenopausal women. However, while the results put Merck's drug ahead for now, the utility of such trials is increasingly in question.<BR />

Published By Datamonitor
23 May 2003
CommentWire
CommentWire

Medigene: new treatments for genital warts

Published By Datamonitor
19 Oct 2001
Expert View
Expert View

Male cancer: side effects scare men off treatments

2.3 million men globally are currently living with one of the so-called male cancers, some are delaying or even refusing treatment when the cancer is at an early stage due to the difficult side effects associated with treatments for these types of cancer. Both the medical and non-medical communities need to act together to help men face up to their battle with cancer.

Published By Datamonitor
18 Oct 2002
CommentWire
CommentWire

Liver cancer: adding radio waves may cut bleeding

Surgeons have shown a new technique to cut blood loss during removal of liver tumors. It involves delivering radio waves to the tumor site during the operation, speeding the rate at which blood clots. Since the blood loss associated with liver tumor removal currently reduces survival rates, this is positive news both for patients and the drug industry.

Published By Datamonitor
05 Nov 2002
Expert View
Expert View

Licensing Week - August 9, 2002

Last week saw a flurry of licensing activity by Bristol-Myers Squibb, as the US-based big pharma extended its drug discovery relationships with Athersys and Exelixis. Genomics also featured heavily last week, as Pfizer, Oxagen, Fujisawa and Quark were all involved in genetic research deals. Finally, Serono signed another marketing deal, this time licensing rights to Genentech's Raptiva.<BR />

Published By Datamonitor
08 Aug 2002
Expert View
Expert View

Licensing Week - August 16, 2002

Last week's licensing news had a truly global feel, with companies from the US, the UK, mainland Europe and Japan getting in on the action. The week saw deals between; AstraZeneca and Xenogen; Crucell and GenVec; Takeda and Human Genome Sciences; Adolor and Eli Lilly; and Anadys and Roche.

Published By Datamonitor
15 Aug 2002

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

No help is available.